Indonesia's Kalbe Farma Reports 14.7 Percent Increase in Net Sales (Indonesia)
This article was originally published in PharmAsia News
Indonesia's Kalbe Farma reported net sales worth $572 million for the first three quarters of 2007. Ninety-five percent of those sales came from within Indonesia with the other 5 percent accounted for by exports. Overall Kalbe's profits are up 14.69 percent compared to the same time period in 2006. (Click here for more
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.